PEN 110

Drug Profile

PEN 110

Alternative Names: INACTINE; INACTINE™ Pathogen Inactivation red blood cell product; INACTINE™ Pathogen Reduction System for Red Cells; PEN110

Latest Information Update: 05 Jul 2005

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Panacos Pharmaceuticals Inc
  • Class Polyamines
  • Mechanism of Action DNA cross linking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Graft-versus-host disease; Infections

Most Recent Events

  • 05 Jul 2005 The INACTINE system is available for licensing (
  • 05 Jul 2005 Discontinued - Phase-III for Infections in USA (Extracorporeal)
  • 05 Jul 2005 Discontinued - Preclinical for Graft-versus-host disease in USA (Extracorporeal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top